A minoxidil pill just posted strong phase 3 results. Up to 86% of men improved coverage in six months. 7/25/2026
VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community New baldness drug boosts hair coverage by up to 86% in six months
A new extended-release oral minoxidil formulation claims to improve hair growth by maintaining steady blood levels, reducing side effects like hypotension, and potentially benefiting female hair loss. However, it is not considered groundbreaking as it builds on existing minoxidil treatments, and its effectiveness compared to current doses is debated.
community How Splitting Oral Minoxidil CHANGED Everything — After 2 Years of Topical Failure
Switching from topical to oral minoxidil, specifically using split dosing, led to significant hair regrowth and reduced side effects for the user. The combination of oral minoxidil and finasteride proved more effective than previous topical treatments.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community Most Promising Future Hair Loss Treatments In 2026
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
Related Research
6 / 6 resultsresearch Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research 76626 Adjunctive Combined Regenerative Technique (CRT) vs Oral Minoxidil Alone for Androgenetic Alopecia: A Six-Month Retrospective Study
CRT is more effective than oral minoxidil alone for treating hair loss.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research 76221 Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment
research Minoxidil oral en alopecias no androgénicas
This literature review explores the mechanism of action, pharmacokinetics, safety, and efficacy of low-dose oral minoxidil as a treatment for various non-androgenic types of alopecia, finding it to be a promising alternative for these conditions despite the need to establish optimal dosing for different demographics.
research Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls
This study observed objective improvement in androgenetic alopecia in 5 out of 6 adolescent girls treated with 2.5 mg oral minoxidil and spironolactone, and reported no adverse effects.